{"id":"standard-dose-ticagrelor","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Bradycardia"},{"rate":"4-6","effect":"Dyspnea"},{"rate":"4-11","effect":"Bleeding (major and minor)"},{"rate":"2-3","effect":"Ventricular pauses"}]},"_chembl":{"chemblId":"CHEMBL398435","moleculeType":"Small molecule","molecularWeight":"522.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, preventing platelet activation and aggregation. Unlike clopidogrel, it does not require hepatic metabolism for activation and provides faster onset of action. This results in reduced platelet-mediated thrombosis and lower risk of cardiovascular events in acute coronary syndromes and other thrombotic conditions.","oneSentence":"Ticagrelor is a P2Y12 receptor antagonist that irreversibly blocks platelet activation and aggregation, reducing thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:12.672Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis"},{"name":"Secondary prevention of atherothrombotic events in patients with prior myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07476898","phase":"PHASE3","title":"Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03-01","conditions":"Stroke","enrollment":864},{"nctId":"NCT05047172","phase":"PHASE3","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-08-02","conditions":"Intracranial Arteriosclerosis, Stroke","enrollment":1683},{"nctId":"NCT06228456","phase":"PHASE4","title":"Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-04-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT06943586","phase":"NA","title":"Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-09","conditions":"Stroke, Transient Ischemic Attack (TIA)","enrollment":200},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT05117866","phase":"NA","title":"Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meditrix Corp","startDate":"2020-09-15","conditions":"Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":307},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04240834","phase":"PHASE4","title":"Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2021-02-01","conditions":"Acute Coronary Syndrome, Interventional Cardiology","enrollment":1220},{"nctId":"NCT04307511","phase":"PHASE4","title":"A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients","status":"RECRUITING","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-04-20","conditions":"Acute Coronary Syndrome Patients With Diabetes After PCI","enrollment":40},{"nctId":"NCT06013020","phase":"PHASE4","title":"Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":374},{"nctId":"NCT06254391","phase":"PHASE2","title":"Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2023-07-03","conditions":"Myocardial Infarction, Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT04255602","phase":"PHASE4","title":"A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-02-19","conditions":"Acute Coronary Syndrome, Coronary Stent Implantation","enrollment":2120},{"nctId":"NCT04307485","phase":"PHASE4","title":"A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2020-03-10","conditions":"Senior Acute Coronary Syndrome Patients After PCI","enrollment":40},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT05831462","phase":"PHASE1, PHASE2","title":"De-escalation of Ticagrelor in Post PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06-01","conditions":"Ticagrelor","enrollment":400},{"nctId":"NCT04718025","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2022-02-07","conditions":"STEMI, NSTEMI, Unstable Angina","enrollment":4500},{"nctId":"NCT03251859","phase":"PHASE3","title":"Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2017-08-11","conditions":"Myocardial Infarction","enrollment":52},{"nctId":"NCT05779059","phase":"PHASE3","title":"Prasugrel Or Ticagrelor De-escalation in NSTE-ACS","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2023-04-01","conditions":"Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina","enrollment":50},{"nctId":"NCT03797651","phase":"NA","title":"Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-04-24","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":2850},{"nctId":"NCT04739384","phase":"PHASE3","title":"Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS","status":"COMPLETED","sponsor":"Federico II University","startDate":"2021-04-01","conditions":"Acute Coronary Syndrome, STEMI, NSTEMI","enrollment":50},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT01813435","phase":"PHASE3","title":"GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2013-07-01","conditions":"Coronary Artery Disease (CAD)","enrollment":15991},{"nctId":"NCT02817789","phase":"PHASE3","title":"Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-05-09","conditions":"Aortic Valve Stenosis","enrollment":50},{"nctId":"NCT02539160","phase":"PHASE4","title":"Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-02","conditions":"Coronary Artery Disease, Diabetes Mellitus","enrollment":101},{"nctId":"NCT05210595","phase":"PHASE4","title":"Optimal Dosage of Ticagrelor in Korean Patients With AMI","status":"UNKNOWN","sponsor":"Dong-A University","startDate":"2022-01-01","conditions":"Acute Myocardial Infarction, Ticagrelor","enrollment":120},{"nctId":"NCT04001894","phase":"PHASE4","title":"Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2019-07-02","conditions":"Platelet Reactivity","enrollment":50},{"nctId":"NCT03679091","phase":"PHASE4","title":"Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-08-29","conditions":"Platelet Reactivity","enrollment":36},{"nctId":"NCT03437044","phase":"PHASE4","title":"Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":40},{"nctId":"NCT04695106","phase":"PHASE4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2021-10-25","conditions":"Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome","enrollment":2230},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT03822377","phase":"PHASE3","title":"Ticagrelor Administered as Standard Tablet or Orodispersible Formulation","status":"COMPLETED","sponsor":"Azienda Ospedaliero Universitaria di Sassari","startDate":"2019-06-27","conditions":"ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI","enrollment":130},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT02617290","phase":"PHASE3","title":"Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-01-09","conditions":"Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction","enrollment":1900},{"nctId":"NCT03989557","phase":"PHASE4","title":"Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms","status":"COMPLETED","sponsor":"Beijing Neurosurgical Institute","startDate":"2019-07-01","conditions":"Unruptured Intracranial Aneurysm, Stents, Antiplatelet Drugs","enrollment":314},{"nctId":"NCT04501900","phase":"PHASE4","title":"The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-10","conditions":"Cardiovascular Diseases","enrollment":2106},{"nctId":"NCT04369534","phase":"PHASE4","title":"Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction","status":"COMPLETED","sponsor":"University of Zagreb","startDate":"2015-12-01","conditions":"Acute Coronary Syndrome, STEMI, NSTEMI - Non-ST Segment Elevation MI","enrollment":120},{"nctId":"NCT04069234","phase":"PHASE3","title":"Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.","status":"WITHDRAWN","sponsor":"Region Skane","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Microvascular Coronary Artery Disease","enrollment":""},{"nctId":"NCT04174261","phase":"PHASE4","title":"Ticagrelor in Remote Ischemic Preconditioning Study","status":"COMPLETED","sponsor":"Hellenic Society of Interventional Cardiology","startDate":"2017-01-29","conditions":"Periprocedural Myocardial Infarction","enrollment":245},{"nctId":"NCT02285751","phase":"PHASE2","title":"High \"on Treatment\" Platelet Reactivity in the Intensive Care Unit","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2012-11","conditions":"Critical Illness","enrollment":200},{"nctId":"NCT02327624","phase":"PHASE4","title":"STEEL Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-06","conditions":"Coronary Artery Disease","enrollment":180},{"nctId":"NCT03620760","phase":"PHASE4","title":"Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation","status":"UNKNOWN","sponsor":"Xiaofan Wu","startDate":"2018-08-07","conditions":"Unstable Angina Pectoris, Coronary Stent Implantation","enrollment":2036},{"nctId":"NCT03381755","phase":"PHASE4","title":"Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-01-01","conditions":"Acute Coronary Syndrome","enrollment":200},{"nctId":"NCT03614832","phase":"PHASE4","title":"Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-05-01","conditions":"Platelet Reactivity","enrollment":100},{"nctId":"NCT03062462","phase":"PHASE2, PHASE3","title":"Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2017-02-10","conditions":"Coronary Artery Disease, Clopidogrel, Poor Metabolism of","enrollment":80},{"nctId":"NCT02422888","phase":"PHASE4","title":"Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2015-05","conditions":"Myocardial Infarction","enrollment":110},{"nctId":"NCT02519608","phase":"PHASE2","title":"ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2015-09","conditions":"Coronary Artery Disease, Chronic Obstructive Pulmonary Disease","enrollment":44},{"nctId":"NCT03273075","phase":"PHASE4","title":"Add-on Cangrelor in STEMI-triggered Cardiac Arrest","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2017-09","conditions":"Cardiopulmonary Arrest With Successful Resuscitation, ACS - Acute Coronary Syndrome, Hypothermia, Induced","enrollment":60},{"nctId":"NCT02319941","phase":"PHASE2","title":"Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2015-05-20","conditions":"Acute Coronary Syndrome","enrollment":65},{"nctId":"NCT02889549","phase":"PHASE2, PHASE3","title":"Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2016-08","conditions":"Coronary Artery Disease","enrollment":60},{"nctId":"NCT02698618","phase":"PHASE4","title":"PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor","status":"UNKNOWN","sponsor":"Fundacion Investigacion Interhospitalaria Cardiovascular","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT01994941","phase":"PHASE4","title":"Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2013-08","conditions":"Acute Coronary Syndrome","enrollment":133},{"nctId":"NCT01731041","phase":"NA","title":"Impact of Ticagrelor Re-load on Pharmacodynamic Profiles","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-01","conditions":"Coronary Artery Disease","enrollment":60},{"nctId":"NCT01898442","phase":"PHASE2","title":"High Ticagrelor Loading Dose in STEMI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-09","conditions":"Coronary Artery Disease","enrollment":52},{"nctId":"NCT02459288","phase":"PHASE4","title":"Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients","status":"UNKNOWN","sponsor":"Ping-Yen Liu","startDate":"2014-01","conditions":"Acute Coronary Syndrome, Chronic Kidney Disease, End-Stage Renal Disease","enrollment":80},{"nctId":"NCT02046486","phase":"PHASE4","title":"OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)","status":"COMPLETED","sponsor":"University of Patras","startDate":"2014-01","conditions":"ST Elevation Myocardial Infarction","enrollment":20},{"nctId":"NCT01543932","phase":"PHASE3","title":"High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2012-07","conditions":"Coronary Artery Disease","enrollment":81},{"nctId":"NCT01575795","phase":"PHASE4","title":"Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"University of Patras","startDate":"2012-04","conditions":"ST-elevation Myocardial Infarction","enrollment":83}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"standard-dose ticagrelor","genericName":"standard-dose ticagrelor","companyName":"First Affiliated Hospital of Harbin Medical University","companyId":"first-affiliated-hospital-of-harbin-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor is a small molecule that acts as a negative allosteric modulator of the P2Y purinoceptor 12, a type of purinergic receptor. It is used in standard-dose form for conditions such as coronary artery disease and coronary stenoses, typically in combination with aspirin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}